These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 11922568)

  • 1. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
    Rosen HR; McHutchison JG; Conrad AJ; Lentz JJ; Marousek G; Rose SL; Zaman A; Taylor K; Chou S
    Am J Gastroenterol; 2002 Mar; 97(3):714-20. PubMed ID: 11922568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
    Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
    Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus.
    Goyal A; Kazim SN; Sakhuja P; Malhotra V; Arora N; Sarin SK
    J Med Virol; 2004 Jan; 72(1):60-5. PubMed ID: 14635012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
    Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Huang JF; Hsieh MY; Wang LY; Yu ML
    J Infect Dis; 2006 Jan; 193(1):98-101. PubMed ID: 16323137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection.
    Yee LJ; Tang J; Herrera J; Kaslow RA; van Leeuwen DJ
    Genes Immun; 2000 Aug; 1(6):386-90. PubMed ID: 11196686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C.
    Dai CY; Chuang WL; Lee LP; Chen SC; Hou NJ; Lin ZY; Hsieh MY; Hsieh MY; Wang LY; Chang WY; Yu ML
    J Viral Hepat; 2006 Nov; 13(11):770-4. PubMed ID: 17052277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of low-density lipoprotein receptor did not affect treatment outcome of chronic hepatitis C genotype 3.
    Tanwandee T; Pithukpakorn M; Vipatakul N; Charatcharoenwitthaya P; Chainuvati S; Nimanong S; Prachayakul V; Pongprasobchai S; Manatsathit S; Leelakusolvong S; Pausawasdi N; Kachintorn U; Limwongse C; Udompunturak S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S147-53. PubMed ID: 21721440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between tumour necrosis factor gene polymorphisms and the clinical types of patients with chronic hepatitis B virus infection.
    Xu XW; Lu MH; Tan DM
    Clin Microbiol Infect; 2005 Jan; 11(1):52-6. PubMed ID: 15649304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms in tumour necrosis factor-alpha, transforming growth factor-beta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection.
    Barrett S; Collins M; Kenny C; Ryan E; Keane CO; Crowe J
    J Med Virol; 2003 Oct; 71(2):212-8. PubMed ID: 12938195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
    Boo I; Fischer AE; Johnson D; Chin R; Giourouki M; Bharadwaj M; Bowden S; Torresi J; Drummer H
    J Clin Virol; 2007 Aug; 39(4):288-94. PubMed ID: 17569577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C.
    Wasmuth HE; Werth A; Mueller T; Berg T; Dietrich CG; Geier A; Gartung C; Lorenzen J; Matern S; Lammert F
    Hepatology; 2004 Aug; 40(2):327-34. PubMed ID: 15368437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.